Literature DB >> 19770288

Postantibiotic effect of ceftaroline against gram-positive organisms.

G A Pankuch1, P C Appelbaum.   

Abstract

The postantibiotic effects (PAEs), postantibiotic sub-MIC effects (PA-SMEs), and sub-MIC effects (SMEs) of ceftaroline, a novel injectable cephalosporin, were determined for 15 gram-positive organisms. The pneumococcal, staphylococcal, and enterococcal PAEs were 0.8 to 1.8 h, 0.7 to 2.2 h, and 0.2 to 1.1 h, respectively. The corresponding PA-SMEs (0.4 times the MIC) were 2.5 to 6.7 h, 2.9 to >0.0 h, and 7.9 to >10.3 h, respectively. The PA-SMEs were longer than the PAEs, suggesting that sub-MIC levels extend the PAE of ceftaroline against gram-positive cocci.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19770288      PMCID: PMC2764186          DOI: 10.1128/AAC.00785-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Postantibiotic effect of ceftobiprole against 12 Gram-positive organisms.

Authors:  G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

2.  Antistaphylococcal activity of the novel cephalosporin CB-181963 (CAB-175).

Authors:  Keith Miller; Christopher Storey; William J Stubbings; Anthony M Hoyle; Joanne K Hobbs; Ian Chopra
Journal:  J Antimicrob Chemother       Date:  2005-02-18       Impact factor: 5.790

Review 3.  The post-antibiotic sub-MIC effect in vitro and in vivo.

Authors:  O Cars; I Odenholt-Tornqvist
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

4.  In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria.

Authors:  I Odenholt; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 5.  Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man.

Authors:  W A Craig
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

6.  In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.

Authors:  Yigong Ge; Donald Biek; George H Talbot; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

7.  In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.

Authors:  Lesley McGee; Donald Biek; Yigong Ge; Magderie Klugman; Mignon du Plessis; Anthony M Smith; Bernard Beall; Cynthia G Whitney; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

8.  Kinetics of antimicrobial activity.

Authors:  B Vogelman; W A Craig
Journal:  J Pediatr       Date:  1986-05       Impact factor: 4.406

9.  Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections.

Authors:  George H Talbot; Dirk Thye; Anita Das; Yigong Ge
Journal:  Antimicrob Agents Chemother       Date:  2007-08-06       Impact factor: 5.191

10.  Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection.

Authors:  Daniel Parish; Noah Scheinfeld
Journal:  Curr Opin Investig Drugs       Date:  2008-02
View more
  9 in total

Review 1.  Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Authors:  Thomas P Lodise; Donald E Low
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

Review 2.  Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

Review 3.  Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

4.  Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Christopher Duplessis; Nancy F Crum-Cianflone
Journal:  Clin Med Rev Ther       Date:  2011-02-10

5.  Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.

Authors:  Alasdair P MacGowan; Alan R Noel; Sharon Tomaselli; Karen E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

6.  In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus.

Authors:  Shawn H MacVane; Wonhee So; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

7.  Effects of intracanal irrigant MTAD Combined with nisin at sub-minimum inhibitory concentration levels on Enterococcus faecalis growth and the expression of pathogenic genes.

Authors:  Zhongchun Tong; Lijia Huang; Junqi Ling; Xueli Mao; Yang Ning; Dongmei Deng
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

8.  Design and pharmacodynamics of recombinant NZ2114 histidine mutants with improved activity against methicillin-resistant Staphylococcus aureus.

Authors:  Huixian Chen; Ruoyu Mao; Da Teng; Xiumin Wang; Ya Hao; Xingjun Feng; Jianhua Wang
Journal:  AMB Express       Date:  2017-02-22       Impact factor: 3.298

9.  Antibacterial and immunomodulatory activities of insect defensins-DLP2 and DLP4 against multidrug-resistant Staphylococcus aureus.

Authors:  Zhanzhan Li; Ruoyu Mao; Da Teng; Ya Hao; Huixian Chen; Xiumin Wang; Xiao Wang; Na Yang; Jianhua Wang
Journal:  Sci Rep       Date:  2017-09-21       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.